Comparative intraperitoneal pharmacokinetics of three platinum analogues.

abstract：PURPOSE:Cyclophosphamide is one of the most frequently used agents in the neoadjuvant, adjuvant, and high-dose chemotherapeutic treatment of breast cancers. Preclinical models indicate that cellular sensitivity to cyclophosphamide and other oxazaphosphorines, e.g., ifosfamide, is inversely related to the cellular conte...

journal_title：Cancer chemotherapy and pharmacology

authors： Sreerama L,Sládek NE

更新日期：2001-03-01 00:00:00

abstract：PURPOSE:Although chemotherapeutic protocols that include chloroethylnitrosoureas (CENUs), such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), have been a mainstay of treatment for glioblastomas, the clinical outcomes ha...

journal_title：Cancer chemotherapy and pharmacology

authors： Narita Y,Asai A,Kuchino Y,Kirino T

更新日期：2000-01-01 00:00:00

abstract：BACKGROUND:We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer. METHODS:Patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueno M,Li CP,Ikeda M,Ishii H,Mizuno N,Yamaguchi T,Ioka T,Oh DY,Ichikawa W,Okusaka T,Matsuyama Y,Arai D,Chen LT,Park YS,Furuse J

更新日期：2017-08-01 00:00:00

abstract：BACKGROUND AND PURPOSE:Human type I fatty acid synthase has been proposed as a chemotherapeutic target for the treatment of breast cancer based on the inactivation of human beta-ketoacyl synthase activity by cerulenin. Triclosan, a common antibiotic, functions by inhibiting the enoyl-reductase enzymes of type II fatty ...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu B,Wang Y,Fillgrove KL,Anderson VE

更新日期：2002-03-01 00:00:00

abstract：BACKGROUND:The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has been widely used as a new and reliable preclinical researc...

journal_title：Cancer chemotherapy and pharmacology

authors： Yang L,Yuan Z,Zhang Y,Cui Z,Li Y,Hou J,Liu X,Liu Z,Shi R,Tian Q,Wang J,Wang L

更新日期：2021-01-01 00:00:00

abstract：:Between December 1982 and November 1990, 31 patients with advanced urothelial carcinoma were treated with one of two combination chemotherapy regimens. A total of 20 patients were treated with 3 mg/m2 mitomycin C and 300 mg/m2 cyclophosphamide given intravenously every 10-14 days and with 180 mg/m2 5-fluorouracil (5-F...

journal_title：Cancer chemotherapy and pharmacology

authors： Sahashi M,Ono Y,Matsuura O,Ohshima S,Fukushima M

更新日期：1992-01-01 00:00:00

abstract：INTRODUCTION:A combined therapy MEK inhibitor, Cobimetinib (CB) and BRAF inhibitor, Vemurafenib (VMF), results in an improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma. VMF skin adverse effects attributed to ERK paradoxical activation are decreased by the adjunction of CB...

journal_title：Cancer chemotherapy and pharmacology

authors： Teuma C,Pelletier S,Amini-Adl M,Perier-Muzet M,Maucort-Boulch D,Thomas L,Laville M,Fouque D,Dalle S

更新日期：2017-05-01 00:00:00

abstract：OBJECTIVE:We evaluated the efficacy and safety of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced metastatic transitional cell carcinoma of the urothelium. SUBJECTS AND METHODS:The subjects were 12 patients diagnosed with advanced metastatic transitional cell carcinoma of th...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamada Y,Itoh Y,Aoki S,Nakamura K,Taki T,Naruse K,Tobiume M,Zennami K,Katsuda R,Kato Y,Watanabe M,Nishikawa G,Minami M,Nakahira M,Ukai S,Sawada M,Kitamura A,Honda N

更新日期：2009-11-01 00:00:00

abstract：PURPOSE:Folate receptor (FR) targeted drug conjugates were prepared by covalently attaching the vitamin folate, to the potent anticancer drug, mitomycin C (MMC). One such conjugate, called EC72, was synthesized with an intramolecular disulfide bond, and it was found to exhibit efficacious anti-tumor activity against FR...

journal_title：Cancer chemotherapy and pharmacology

authors： Reddy JA,Westrick E,Vlahov I,Howard SJ,Santhapuram HK,Leamon CP

更新日期：2006-08-01 00:00:00

abstract：INTRODUCTION:Despite the extensive clinical experience with irinotecan, significant concerns remain regarding its toxicity. In a phase I trial, we modulated irinotecan pharmacokinetics by inhibiting biliary excretion of SN-38, the active metabolite of irinotecan, using cyclosporine. The modulation appeared to decrease ...

journal_title：Cancer chemotherapy and pharmacology

authors： Desai AA,Kindler HL,Taber D,Agamah E,Mani S,Wade-Oliver K,Ratain MJ,Vokes EE

更新日期：2005-10-01 00:00:00

abstract：BACKGROUND:Chemoresistance is a common problem for cancer treatment worldwide. Circulating exosomal microRNAs (miRNAs) have been considered as promising biomarkers of cancers. However, few studies have assessed the relationship between serum/plasma exosomal microRNAs and chemoresistance in colorectal cancer (CRC). MET...

journal_title：Cancer chemotherapy and pharmacology

authors： Jin G,Liu Y,Zhang J,Bian Z,Yao S,Fei B,Zhou L,Yin Y,Huang Z

更新日期：2019-08-01 00:00:00

abstract：PURPOSE:Recently, it was shown that chrysin causes upregulation of UGT1A1 in Caco-2 intestinal cells. Therefore, we proposed that oral chrysin may reduce irinotecan (CPT-11) induced diarrhoea by shifting the SN-38G/SN-38 equilibrium towards the inactive SN-38G in the gastrointestinal mucosa. The purpose of this study w...

journal_title：Cancer chemotherapy and pharmacology

authors： Tobin PJ,Beale P,Noney L,Liddell S,Rivory LP,Clarke S

更新日期：2006-02-01 00:00:00

abstract：PURPOSE:The aims of this dose-escalating phase I study were to determine the maximum tolerable dose (MTD) and recommended dose (RD) of 5-fluorouracil (5-FU), docetaxel, and nedaplatin (UDON) combination therapy for future phase II studies, and to evaluate the safety and efficacy of this regimen in patients with untreat...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueda S,Kawakami H,Nishina S,Sakiyama T,Nonagase Y,Okabe T,Tamura T,Nakagawa K

更新日期：2015-08-01 00:00:00

abstract：BACKGROUND:The pharmacokinetics and tissue distribution of photofrin II (PF) and its efficacy in sonodynamic therapy were studied in rats bearing AH130 solid tumors. MATERIALS AND METHODS:In order to find the optimum timing of the ultrasound exposure after administration of PF, the PF concentrations in plasma, skin, m...

journal_title：Cancer chemotherapy and pharmacology

authors： Yumita N,Umemura S

更新日期：2003-02-01 00:00:00

abstract：PURPOSE:Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies. The purpose of this study was to assess the efficacy of a combination of docetaxel, capecitabine, and cisplatin (TXP) in patients diagnosed w...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu YS,Chen DR,Tseng LM,Yeh DC,Chen ST,Hsieh CM,Wang HC,Yeh HT,Kuo SH,Huang CS

更新日期：2011-06-01 00:00:00

abstract：:The present study deals with the influence of some bis(eta 5-cyclopentadienyl)titanium(IV) (titanocene) complexes, mainly represented by titanocene dichloride, on the development of several human gastrointestinal (GI) carcinomas (one stomach, seven colon, four sigmoid, and two rectal adenocarcinomas), all xenografted ...

journal_title：Cancer chemotherapy and pharmacology

authors： Köpf-Maier P

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:Epigenetic agents are among the newly targeted therapeutic strategies being studied with intense interest for patients with multiple myeloma. Here, we demonstrate the antitumor activity of a phenylbutyrate-based histone deacetylase (HDAC) inhibitor, (S)-HDAC42, and identify its possible targets in myeloma cells...

journal_title：Cancer chemotherapy and pharmacology

authors： Bai LY,Omar HA,Chiu CF,Chi ZP,Hu JL,Weng JR

更新日期：2011-08-01 00:00:00

abstract：:A phase I trial of indicine-N-oxide was carried out in 12 children with solid tumors and in 16 with leukemia. Doses of 5, 6, and 7.5 g/m2 were given parenterally as a 15-min infusion every 3 weeks. The maximum tolerated dose in patients with solid tumors was 7.5 g/m2 and the dose-limiting toxicity was myelosuppression...

journal_title：Cancer chemotherapy and pharmacology

authors： Whitehead VM,Bernstein ML,Vega R,Vats T,Dyment P,Vietti TJ,Krischer J

更新日期：1990-01-01 00:00:00

abstract：BACKGROUND:Fenretinide is a synthetic retinoid that can induce cytotoxicity by several mechanisms. Achieving effective systemic exposure with oral formulations has been challenging. An intravenous lipid emulsion fenretinide formulation was developed to overcome this barrier. We conducted a study to establish the maximu...

journal_title：Cancer chemotherapy and pharmacology

authors： Thomas JS,El-Khoueiry AB,Maurer BJ,Groshen S,Pinski JK,Cobos E,Gandara DR,Lenz HJ,Kang MH,Reynolds CP,Newman EM

更新日期：2021-01-10 00:00:00

abstract：PURPOSE:Oxaliplatin and satraplatin demonstrate activity against cisplatin-resistant tumor cells. Although the two platinum analogs are structurally-related, oxaliplatin is more active. Therefore, studies focusing on protein expression profiling were undertaken to identify the molecular mechanism for the difference in ...

journal_title：Cancer chemotherapy and pharmacology

authors： He G,Xie X,Siddik ZH

更新日期：2020-06-01 00:00:00

abstract：:The therapeutic efficacy of PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl, was evaluated using the transplantable L1210 leukemia and Ridgway osteogenic sarcoma tumor lines and the spontaneous C3H/StRos mammary tumor and AKR leukemia tumor models. Given in a single i.p. dose at 5-10 mg/kg on day 2 or...

journal_title：Cancer chemotherapy and pharmacology

authors： Yagi MJ,Bekesi JG

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:High-dose methotrexate (HD-MTX) is widely used in the treatment of non-Hodgkin lymphoma (NHL), but the pharmacokinetic properties of HD-MTX in Chinese adult patients with NHL have not yet been established through an approach that integrates genetic covariates. The purposes of this study were to identify both ph...

journal_title：Cancer chemotherapy and pharmacology

authors： Yang L,Wu H,de Winter BCM,Sheng CC,Qiu HQ,Cheng Y,Chen J,Zhao QL,Huang J,Jiao Z,Xie RX

更新日期：2020-05-01 00:00:00

abstract：PURPOSE:Polyamines are biologic cations necessary for normal cell growth. Polyamine analogues have been shown to be effective inhibitors of tumor growth. We tested the effect of the polyamine analogues 1,1 9-bis(ethylamino)-5,10,15-triazanonadecane (BE-4-4-4-4), N1,N11-bis(ethyl)norspermine (BE-3-3-3) and 1,15-bis(ethy...

journal_title：Cancer chemotherapy and pharmacology

authors： Jeffers L,Church D,Basu H,Marton L,Wilding G

更新日期：1997-01-01 00:00:00

abstract：:Ankinomycin is a new antitumor antibiotic found in the culture broth of Streptomyces sp. SF2587. Ankinomycin showed marked cytotoxicity and antitumor activity against some murine leukemias, but the activity against murine solid tumors was rather weak because of its strong acute toxicity. We synthesized ankinomycin acy...

journal_title：Cancer chemotherapy and pharmacology

authors： Ishii S,Satoh Y,Tsuruo T

更新日期：1993-01-01 00:00:00

abstract：:A human tumor clonogenic assay (HTCA) has been used to evaluate standard and experimental anticancer drugs with respect to their inhibition of clonogenicity of both fresh human cancers and human tumor cell lines. By comparing the inhibitory effect on tumor colony-forming unit (TCFU) growth of 1-h and continuous drug e...

journal_title：Cancer chemotherapy and pharmacology

authors： Ludwig R,Alberts DS,Miller TP,Salmon SE

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:Tomudex is a second-generation folate analogue that when polyglutamated is a potent inhibitor of thymidylate synthase (TS). METHODS:Based on indications of antitumor activity in phase I trials, the Gynecologic Oncology Group initiated a phase II study of Tomudex 3 mg/m2 intravenously every 3 weeks in patients ...

journal_title：Cancer chemotherapy and pharmacology

authors： Muggia FM,Blessing JA,Homesley HD,Sorosky J

更新日期：1998-01-01 00:00:00

abstract：:The ability of the polysulfonated antitumor drug suramin and six related polysulfonated azo dyes to inhibit the cell growth, platelet-derived growth factor (PDGF)-receptor binding, and intracellular Ca2+ signaling of Swiss 3T3 fibroblasts was studied. Some of the azo dyes were more potent inhibitors of PDGF binding th...

journal_title：Cancer chemotherapy and pharmacology

authors： Powis G,Seewald MJ,Melder D,Hoke M,Gratas C,Christensen TA,Chapman DE

更新日期：1992-01-01 00:00:00

abstract：:Previously, we showed that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC), isolated from the buds of Cleistocalyx operculatus, significantly inhibited the growth of human liver cancer SMMC-7721 cells and could induce SMMC-7721 cells apoptosis in vitro. Here, we report the antitumor effects of DMC in vivo, usi...

journal_title：Cancer chemotherapy and pharmacology

authors： Ye CL,Liu JW,Wei DZ,Lu YH,Qian F

更新日期：2005-05-01 00:00:00

abstract：:A simple fluorescent microscopic method demonstrated that adriamycin was distributed in two cellular compartments of living rat colon cancer cells. Adriamycin accumulated slowly in cytoplasmic granules, probably lysosomes, where it persisted long after the drug was removed from the medium. On the other hand, adriamyci...

journal_title：Cancer chemotherapy and pharmacology

authors： Chauffert B,Martin F,Caignard A,Jeannin JF,Leclerc A

更新日期：1984-01-01 00:00:00

abstract：:Sodium cyanate (NaOCN) at a dose of 250 mg/kg was shown to decrease protein synthesis in P388 leukemia tumor cells to approximately 52% of control values at 2 h and 32% at 5 h after NaOCN administration, without a corresponding decrease in various normal tissues of the tumor-bearing CD2Fl mice. CD2Fl mice that had rec...

journal_title：Cancer chemotherapy and pharmacology

authors： Dufour M,St Germain J,Skalski V,Dorato A,Lazarus P,Panasci LC

更新日期：1984-01-01 00:00:00